CMPX · Compass Therapeutics, Inc.
$0.96
+0.10 (+12.13%)
At close · Oct 5
Return incl. dividend (before tax)
Market Cap
$193.41M
Shares
180.09M
Volume · Oct 5
15.83M
Avg daily vol (3M)
3.99M
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$0.96
Open$0.91
Day$0.89–1.00
52W close$0.86–6.69
Avg vol 30d5.2M
Short int41.6M · 23.1% float · 16.0d
Short vol50%
Last earningsMay 20, 2026
DataApr 2021–Oct 2026
Filing10-Q · Aug 6
Up next
Next earnings call
Nov 26, 2026
Est · unconfirmed
· in 7 wks
filed Aug 6, 2026
Metrics snapshot
Useful current figures from the complete screener profile.
Revenue (TTM)
—
Trailing 12 months
Net income (TTM)
−$73.45M
Trailing 12 months
Revenue growth YoY
-100.0%
Year over year
Operating margin
—
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
-29.1%
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
—
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+30.2%
Year over year · more shares
Price change (1Y)
-75.3%
Trailing year
Short interest
23.1%
Latest settlement · 16.0 days to cover
Equibles Rating
blended score · not investment adviceOverall
Strong Sell
SellHoldBuy
Technical
Strong Sell
Momentum
Very Weak
Sentiment
Bullish
Fundamentals
Weak
Quant / Vol
Very High
Market backdrop
VIX 15.5 · calm
Equity put/call 0.59
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
−73%
below
Price vs 50-day avg
−51%
below
RSI (14)
22
oversold
MACD trend
Negative
52-week position
2%
near low
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
1-month return
−60%
trailing
6-month return
−82%
trailing
YTD return
−82%
this year
Relative strength
−94%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $2 › 200d $4 — 200d above 50d
Institutional flow
Accumulating
+5% holders QoQ · +63 funds added
Insider flow
Accumulating
Net +$21.3K over 90 days · 0% sells
Short interest
Rising
23.13% of float · ▲ +2.1% MoM · 16.0 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
215 holders — near 3-yr high, broad support
Squeeze score
64
elevated · 0–100
Fundamentals
Revenue growth
−100%
Y/Y
Free cash flow
$-49.2M
Balance sheet
$144.5M
net cash
Quant / Vol
risk profile
Volatility
96%
annualized · 1-yr
Max drawdown
−87%
past year
ATR
13.7%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders Strong Sell
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
−73%
Bearish
Price vs 50-day avg
−51%
Bearish
RSI (14)
22
Neutral
MACD trend
Negative
Bearish
52-week position
2%
Bearish
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
Bullish · 3 of 6
Trend (MA cross)
No cross
50d $2 › 200d $4 — 200d above 50d
Institutional flow
Accumulating
+5% holders QoQ · +63 funds added
Insider flow
Accumulating
Net +$21.3K over 90 days · 0% sells
Short interest
Rising
23.13% of float · ▲ +2.1% MoM · 16.0 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
215 holders — near 3-yr high, broad support
Price context
position in its 52-week range
Range low $1
Now $1 · 2%
Range high $7
vs 200-day avg -73%
vs 50-day avg -51%
Illustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
Earlier KPI extraction records exist, but do not meet the current evidence-completeness requirements. No current verified series is available. Earlier figures remain withheld until revalidated; this is not evidence that the company reports no KPIs.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
CMPX
this stock
Compass Therapeutics, Inc.
|
$193.41M | -82.1% | -100.0% | — | 23.1% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$133.37B | +11.1% | +46.2% | 30.7 | 1.9% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$81.13B | -5.9% | +20.8% | 19.5 | 2.5% |
|
MRNA
Moderna, Inc.
|
$79.40B | +589.1% | +4.3% | — | 8.2% |
|
CSLLY
Csl Ltd
|
$61.25B | — | — | — | 0.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Smart Money
Financials
Filings
Earnings & Events
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| CMPX | -13.5% | -59.6% | -82.3% | -7.6% | -82.1% |
| SPY | +1.2% | +0.6% | +11.6% | +1.6% | +13.6% |
| vs SPY | -14.7% | -60.2% | -93.9% | -9.2% | -95.7% |